InspireMD (NYSE:NSPR – Get Free Report) and Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.
Profitability
This table compares InspireMD and Bluejay Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InspireMD | -413.96% | -69.42% | -57.68% |
| Bluejay Diagnostics | N/A | -155.67% | -117.82% |
Institutional & Insider Ownership
44.8% of InspireMD shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 29.7% of InspireMD shares are owned by company insiders. Comparatively, 0.4% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InspireMD | 0 | 0 | 2 | 0 | 3.00 |
| Bluejay Diagnostics | 0 | 0 | 0 | 0 | 0.00 |
InspireMD currently has a consensus target price of $4.75, suggesting a potential upside of 67.25%. Given InspireMD’s stronger consensus rating and higher probable upside, equities analysts clearly believe InspireMD is more favorable than Bluejay Diagnostics.
Risk and Volatility
InspireMD has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.
Earnings and Valuation
This table compares InspireMD and Bluejay Diagnostics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InspireMD | $6.82 million | 10.86 | -$19.92 million | ($0.75) | -3.79 |
| Bluejay Diagnostics | $250,000.00 | 9.27 | -$9.95 million | ($1,372.00) | 0.00 |
Bluejay Diagnostics has lower revenue, but higher earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
InspireMD beats Bluejay Diagnostics on 11 of the 14 factors compared between the two stocks.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.
